Skip to content

Digital Twins: A Revolutionary Role in Pharmaceutical Manufacturing

The pharmaceutical industry is at the brink of a technological revolution that promises to redefine the way medicines are produced. As the lines between the physical and digital worlds blur, an innovative concept emerges – Digital Twins.

A digital twin is an advanced virtual model that mirrors a physical object or system with detail and accuracy. It is not a static representation but a dynamic and evolving digital counterpart that interacts with real-time data and advanced analytics. This powerful tool can predict the performance of its physical counterpart, estimate disruptions, optimise supply chain operations and propose solutions. For leaders this will be a powerful tool in their arsenal to enhance decision-making, drive operational efficiency, and innovation.

The Impact of Digital Twins on Drug Production

Digital twins bring a transformative potential to drug production. By harnessing the capabilities of this technology, manufacturers can dramatically increase efficiency, actively ensure product quality and substantially reduce downtime. By simulating the pharmaceutical manufacturing processes before they are physically implemented, digital twins present opportunities for more sustainable process development, in turn reducing experimentation time and lowering product waste, leading to more reliable and quality-focused production.

The concept extends beyond just simulation. Digital twins have become an integral part of the production lifecycle; from design to retirement. It offers insights for “Quality by Design” models, making it possible to get the product right, on the first time. Real-time monitoring of production processes allows for swift corrective measures, ensuring the drugs produced meet stringent quality standards consistently.

The Evolution of Digital Twins in Pharma

What began as straightforward simulations has matured into intricate systems that harmonise with the Internet of Things, Artificial Intelligence and Machine Learning. This evolution is underpinned by significant technological advancements and is now a pivotal element in the era of Pharma Industry 4.0.

Previously, the idea of a digital twin was more theoretical than practical, a vision rather than an operational tool. Over time, as computational power increased and data analytics gained sophistication, so did the capabilities of digital twins. They have evolved into critical components for optimising pharmaceutical processes, enabling predictive maintenance and designing more efficient products. Smart manufacturing relies on the digital twins model.

They are the foundation for automated systems that foster interconnectedness in the manufacturing and production environment, in other terms, digital twins allow machinery and equipment to learn from and communicate with one another, reducing human intervention and optimising the overall production cycle. Few key advantages of adopting digital twin technology include the following:

1. Enhanced Decision-Making Through Predictive Analytics

  • Simulate different scenarios and anticipate outcomes for proactive strategies.
  • Leverage data for informed, strategic business decisions.
  • 2. Increased Production and Reduced Waste

  • Optimise manufacturing processes for enhanced yield.
  • Minimise waste through precise modelling and process control.
  • 3. Better Compliance and Quality Control

  • Maintain stringent regulatory compliance with continuous monitoring.
  • Ensure consistent high quality production output.
  • 4. Improved Efficiency in Research and Development

  • Accelerate R&D cycles with virtual testing and modelling.
  • Reduce the need for physical prototypes, saving time and resources.
  • 5. Customisation in Production

  • Create tailored drug formulations and dosages using patient-specific data.
  • Enhance patient outcomes using personalised medicine approaches.
  • What are the Challenges of Digital Twins in Pharma

    The path to adopting this transformative technology comes with a unique set of challenges and considerations that businesses must navigate.

    Integrating with Existing Systems

    Digital twins require a synchronicity with current systems to function effectively. This process often demands significant modifications to legacy systems, adaptations in workflow and in some cases, a complete overhaul of the IT architecture. Ensuring that the digital twin can communicate and synchronise with numerous databases and software requires meticulous planning and strategic implementation.

    Data Privacy and Security Concerns

    As digital twins rely heavily on data, concerns regarding privacy and security are paramount. The vast amounts of sensitive data collected and analysed by digital twins must be protected against breaches and unauthorised access. This leads to the incorporation of robust cybersecurity measures, rigorous compliance with data protection regulations and a clear understanding of who has access to the data.

    High Initial Investment and Skilled Personnel

    The deployment of digital twin technology comes with a high initial cost. As this is a highly sophisticated technology, skilled professionals are needed to navigate the complexities of AI, machine learning and data analytics. Sourcing skilled talent capable of managing and interpreting the intricacies as well as conducting ongoing maintenance and regularly updating digital twin models contribute to the total cost of ownership, making it a significant long-term investment.

    The Future of Digital Twins

    Digital twins stand out as a beacon of advancement, particularly with the integration of AI and ML which will propel these benefits to new heights. AI algorithms can analyse complex datasets derived from digital twins to uncover patterns and insights that would otherwise go unnoticed. These could range from optimising supply chains to pin-pointing inefficiencies in manufacturing processes. AI-driven digital twins can forecast and simulate the implications of making changes to these processes, in turn, mitigating risk and enhancing decision-making.

    In clinical trials, AI-enhanced digital twins can be used to simulate patient responses, potentially reducing the number of real world trials required and accelerating the drug development pipeline. They can also contribute to personalised medicine by modeling how different patient demographics might respond to drugs based on genetics, lifestyle and environmental factors.

    The OneSC Approach

    Our OneSC platform is in the process of developing an advanced AI-based software called TwinNet. Designed as a comprehensive digital twin for supply chain management, TwinNet provides an expansive, real-time view of pharmaceutical supply chains. This advanced software stands out by aiding operational teams as they navigate complex decisions, helping to avoid delays and prevent product loss.

    By addressing the challenges of supply chain disruptions, especially those related to regulatory compliance (a notable hurdle in the life sciences sector). Supply chain partners can enhance their operational resilience and ensure continuous delivery of critical products. Equipped to be the centralised hub for inventory management, order processing and emergency recovery, it grants unparalleled transparency into the real-time functionality of supply chains.

    What sets TwinNet apart from others in this space, is its capacity to integrate the processing of critical documents and ensure adherence to quality assurance standards. Utilising simulations and optimisation models that take into account the entire supply chain, it eclipses traditional analytics methods that have become outdated within the pharmaceutical industry’s supply chain management.

    The implementation of TwinNet is poised to significantly reduce errors, with estimates suggesting a potential decrease of 20-50%. This can lead to a notable drop in lost sales and product shortages, by as much as 65%. Additional advantages of this innovative platform include a reduction in warehousing expenses by 10% and a 40% decrease in administrative costs, contributing to a lower carbon footprint for products.

    This aligns with OneSC’s commitment to contributing to public health and underscores the broader impacts of technological advancements in the pharmaceutical sector.

    Discover our advancements in AI technology at the leading pharmaceutical exhibition – Making Pharmaceuticals. Taking place at the Coventry Building Society Arena on April 23-24th. Our presentation is scheduled for 2:30pm on April 23rd. Please drop by at booth 114 to learn more on how OneSC can help your business grow.

    Leave a Reply

    Your email address will not be published. Required fields are marked *